<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066947</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <secondary_id>WRI-GEV-007</secondary_id>
    <nct_id>NCT03066947</nct_id>
  </id_info>
  <brief_title>SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer</brief_title>
  <official_title>A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BriaCell Therapeutics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Insight, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BriaCell Therapeutics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast&#xD;
      cancer. Eligible patients will have histological confirmation of breast cancer with recurrent&#xD;
      and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose&#xD;
      cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and&#xD;
      upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of&#xD;
      inoculation ~2 and ~4 days after the inoculation. These is repeated every 2 weeks for one&#xD;
      month (3 treatments), then monthly for up to one year. Standard tumor assessments are&#xD;
      performed at baseline and then every 2-3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open label study of SV-BR-1-GM in recurrent and/or metastatic breast&#xD;
      cancer. The detailed treatment regimen follows:&#xD;
&#xD;
      Pre-Inoculation Regimen:&#xD;
&#xD;
      Cyclophosphamide (Cytoxan) 300 mg/m^2 I.V., 1x only, will be given 48-72 hours before each&#xD;
      SV-BR-1-GM inoculation, with an antiemetic of the provider's choice (steroids prohibited). If&#xD;
      the patient is not tolerating the cyclophosphamide, a lower dose may be used (e.g. 200 or 150&#xD;
      mg/m^2) or it may be withheld, with the Sponsor's approval.&#xD;
&#xD;
      Innoculation Day Standard Operating Procedures:&#xD;
&#xD;
        1. Inquire regarding events of past weeks, change in medications, pain scale, ECOG scale,&#xD;
           and review of systems.&#xD;
&#xD;
        2. Check injection sites.&#xD;
&#xD;
        3. Perform DTH skin test intra-dermally with the SV-BR-1 parent cell line (~1 x 10^6&#xD;
           irradiated tumor cells). Observe about 20 minutes for acute hypersensitivity. Grade III&#xD;
           or higher acute hypersensitivity will abort therapy.&#xD;
&#xD;
        4. Inject SV-BR-1-GM intra-dermally into 4 sites in thighs and upper back (0.5 mL each).&#xD;
           Monitor patients for 60 minutes. Vital signs will be assessed and medical attention will&#xD;
           be warranted if unstable.&#xD;
&#xD;
      SV-BR-1-GM Preparation &amp; Inoculation Regimen:&#xD;
&#xD;
      Each inoculation will be administered via intra-dermal injection at the investigational&#xD;
      sites. Subjects will receive 15-25 x 10^6 viable, irradiated transfected breast tumor cells&#xD;
      in a total volume of 2.0 ml Ringer's lactate. SV-BR-1-GM cells will be irradiated to ensure&#xD;
      cell replication incompetency.&#xD;
&#xD;
      SV-BR-1-GM will be divided into four aliquots of 0.5 mL each and injected intra-dermally; one&#xD;
      each into the anterior skin of the subject's right and left thighs and over the right and&#xD;
      left upper back . Application of anesthetic lidocaine crème may be used if necessary for&#xD;
      control of local pain before inoculation. Subjects will be monitored for 60 minutes.&#xD;
&#xD;
      After at least 10 subjects have been treated safely with this regimen, the dose of SV-BR-1-GM&#xD;
      may be escalated or decreased in subsequent patients based on the emerging data.&#xD;
&#xD;
      Post-Inoculation Regimen:&#xD;
&#xD;
      2 days (± 1 day) after inoculation, and again 4 days (± 1 day) later after inoculation, the&#xD;
      patient will return to the principal investigator's office to receive Interferon-alpha-2b&#xD;
      (Merck) in 0.1 mL saline, prepared as follows: These will also be provided by the sponsor and&#xD;
      injected intra-dermally to each inoculation site, beneath the thickest area. Again, subjects&#xD;
      will be observed about 20 minutes. The DTH response will also be recorded at the 2 days (± 1&#xD;
      day) visit.&#xD;
&#xD;
      This cycle will be performed every 2 weeks for the first month of treatment (3 inoculations),&#xD;
      and then every month for up to one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">November 22, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety]</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the number of patients with toxicity events while on SV-BR-1-GM, as defined by the Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment Emergent Adverse Events [Safety]</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the duration of toxicity events while on SV-BR-1-GM, as defined by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Adverse Event Related to SV-BR-1-GM Administration [Safety]</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the number of participants with an adverse event related to SV-BR-1-GM administration, as defined by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response Rate</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Objective response rate (ORR), defined as complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) and immune-related RECIST (iRECIST) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Non-progression of Tumors</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Non-progressive rate, defined as CR, PR or stable disease (SD) per RECIST and iRECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of Tumor Response</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Durability of response, as defined as complete response (disappearance of all tumors), partial response (30% or greater reduction in the sum of diameters of target lesions (tumors) with stable disease in non-target lesions) or stable disease (less than 20% increase in the sum of diameters of target lesions with no new lesions appearing) by evaluating those patients eligible to complete the optional treatments from 9-12 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune Responses to Vaccine</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To assess immune responses to SV-BR-1-GM, and to recall antigens, if any, as measured by DTH skin tests and/or other immunological tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Using the SF-36 Health Survey</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To measure the quality of life (QOL) of participants using the SF-36 Health Survey, which includes measures of General Health, Limitations of Activity, Physical Health Problems, Emotional Health Problems, Social Activities, Energy and Emotions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To measure changes in weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Performance Status</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To measure changes in performance status using the Eastern Cooperative Oncology Group (ECOG) scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain (Pain Scale)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To measure changes in pain using a scale from None to Very Mild to Mild to Moderate to Severe to Very Severe</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breastcancer</condition>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>SV-BR-1-GM Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SV-BR-1-GM</intervention_name>
    <description>See above</description>
    <arm_group_label>SV-BR-1-GM Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Low dose pre-treatment to reduce regulatory T cells</description>
    <arm_group_label>SV-BR-1-GM Monotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interferon-alpha-2b</intervention_name>
    <description>Low dose given in the vaccine site to boost the immune response</description>
    <arm_group_label>SV-BR-1-GM Monotherapy</arm_group_label>
    <other_name>Intron A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Have histological confirmation of breast cancer with recurrent and/or metastatic&#xD;
             lesions via investigational site.&#xD;
&#xD;
               -  Patients with new or progressive breast cancer metastatic to brain will be&#xD;
                  eligible provided:&#xD;
&#xD;
                    1. There is no need for steroids and patients have not had steroids at least 2&#xD;
                       weeks&#xD;
&#xD;
                    2. No individual tumor size is &gt;50 mm3&#xD;
&#xD;
                    3. ECOG status &lt;3&#xD;
&#xD;
                    4. Tumor is not impinging on Middle Cerebral Artery/speech-motor strip&#xD;
&#xD;
                    5. If surgically debulked, must be healed from surgery and at least 3 weeks&#xD;
                       have elapsed since general anesthesia&#xD;
&#xD;
                    6. Patients consent to MRI studies at 3-4 week intervals until evidence of&#xD;
                       tumor regression on at least 2 imaging studies. In no case, will the&#xD;
                       interval between MRI studies be longer than 3 months. MRI study may be&#xD;
                       introduced at any time should the patients develop new or clearly worsening&#xD;
                       symptoms and/or introduction of steroids&#xD;
&#xD;
                       2. Have evidence of persistent, recurrent, or progressive disease for which&#xD;
                       there is no known or established treatment available with curative intent,&#xD;
                       after failing at least one course of community standard systemic treatment&#xD;
                       with chemotherapy (and endocrine therapy if appropriate)&#xD;
&#xD;
                       3. Be 18 years of age or older and female&#xD;
&#xD;
                       4. Have expected survival of at least 4 months&#xD;
&#xD;
                       5. Have adequate performance status (ECOG 0-2)&#xD;
&#xD;
                       6. Patients may be maintained on hormonal therapy provided there is clear&#xD;
                       evidence of tumor progression&#xD;
&#xD;
                       7. Have provided written informed consent.&#xD;
&#xD;
                       Exclusion Criteria:&#xD;
&#xD;
               1. Concurrent or recent chemotherapy (within 3 weeks), XRT within 3 weeks, may have&#xD;
                  had immunotherapy in the past (off within 3 weeks), or general anesthesia/major&#xD;
                  surgery (within 3 weeks). Patients must have recovered from all known or expected&#xD;
                  toxicities from previous treatment and passed a treatment-free &quot;washout&quot; period&#xD;
                  of 3 weeks before starting this program (8 weeks for persons receiving&#xD;
                  nitrosourea or mitomycin).&#xD;
&#xD;
               2. History of clinical hypersensitivity to GM-CSF, Interferon-alpha-2b (Merck),&#xD;
                  yeast, beef, or to any components used in the preparation of the experimental&#xD;
                  vaccine.&#xD;
&#xD;
               3. BUN &gt;30 and a creatinine &gt;2.&#xD;
&#xD;
               4. Absolute granulocyte count &lt; 1000; platelets &lt;100,000.&#xD;
&#xD;
               5. Bilirubin &gt;2.0; alkaline phosphatase &gt;5x upper limit of normal (ULN); ALT/AST &gt;2x&#xD;
                  ULN.&#xD;
&#xD;
               6. Proteinuria &gt;1+ on urinalysis or &gt;1 gm/24hr.&#xD;
&#xD;
               7. Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA&#xD;
                  scan) below the normal limits of the institutions specific testing range. This&#xD;
                  assessment may be repeated once at the discretion of the Investigator with the&#xD;
                  approval of the Sponsor.&#xD;
&#xD;
               8. New York Heart Association stage 3 or 4 cardiac disease.&#xD;
&#xD;
               9. A pleural effusion of moderate severity or worse.&#xD;
&#xD;
              10. Any woman of childbearing potential, unless she:&#xD;
&#xD;
                    1. Agrees to take measures to avoid becoming pregnant during the study and&#xD;
&#xD;
                    2. Has a negative serum pregnancy test within 7 days prior to starting&#xD;
                       treatment.&#xD;
&#xD;
              11. Women who are pregnant or nursing.&#xD;
&#xD;
              12. Patients with concurrent second malignancy. Persons with previous malignancies&#xD;
                  effectively treated and not requiring treatment for &gt;24 months are eligible,&#xD;
                  provided there is unambiguous documentation that current local recurrence or&#xD;
                  metastatic site represents recurrence of the primary breast malignancy.&#xD;
&#xD;
              13. Patients who are HIV positive (by self-report) or have clinical or laboratory&#xD;
                  features indicative of AIDS.&#xD;
&#xD;
              14. 14. Patients who require systemic steroids at a dose equivalent of &gt;10 mg/day of&#xD;
                  prednisone. Beta-blocker therapy, while not exclusionary, is discouraged and&#xD;
                  alternatives should be sought if possible. The beta-blocker might compromise use&#xD;
                  of epinephrine for the rare possibility of anaphylaxis. Anticoagulants must be&#xD;
                  approved by the Investigator with notification of the Sponsor.&#xD;
&#xD;
              15. Patients who are on treatment for rheumatological or autoimmune disease unless&#xD;
                  approved by the Investigator in consultation with the Sponsor (e.g., as for&#xD;
                  replacement therapy for autoimmune thyroiditis or diabetes).&#xD;
&#xD;
              16. Patients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline&#xD;
                  personality disorder) or other clinically progressive major medical problems,&#xD;
                  unless approved by the PI.&#xD;
&#xD;
              17. Male breast cancer patients.&#xD;
&#xD;
              18. Patients may not be on a concurrent clinical trial, unless approved by PI.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George E Peoples, MD, FACS</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Insight, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Sylvester at Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas (CCK)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancerinsight.com/</url>
    <description>CRO Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03066947/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SV-BR-1-GM Monotherapy</title>
          <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with Advanced Breast Cancer</population>
      <group_list>
        <group group_id="B1">
          <title>SV-BR-1-GM Monotherapy</title>
          <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety]</title>
        <description>To evaluate the number of patients with toxicity events while on SV-BR-1-GM, as defined by the Common Terminology Criteria for Adverse Events (CTCAE)</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>All patients</population>
        <group_list>
          <group group_id="O1">
            <title>SV-BR-1-GM Monotherapy</title>
            <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety]</title>
          <description>To evaluate the number of patients with toxicity events while on SV-BR-1-GM, as defined by the Common Terminology Criteria for Adverse Events (CTCAE)</description>
          <population>All patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu like symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGTP increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Tract Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal distension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Multiforme</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleural Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Treatment Emergent Adverse Events [Safety]</title>
        <description>To evaluate the duration of toxicity events while on SV-BR-1-GM, as defined by CTCAE</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Median Duration</title>
            <description>Median duration of adverse events</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment Emergent Adverse Events [Safety]</title>
          <description>To evaluate the duration of toxicity events while on SV-BR-1-GM, as defined by CTCAE</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="0" upper_limit="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Adverse Event Related to SV-BR-1-GM Administration [Safety]</title>
        <description>To evaluate the number of participants with an adverse event related to SV-BR-1-GM administration, as defined by CTCAE</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>Number with related adverse events</population>
        <group_list>
          <group group_id="O1">
            <title>SV-BR-1-GM Monotherapy</title>
            <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event Related to SV-BR-1-GM Administration [Safety]</title>
          <description>To evaluate the number of participants with an adverse event related to SV-BR-1-GM administration, as defined by CTCAE</description>
          <population>Number with related adverse events</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response Rate</title>
        <description>Objective response rate (ORR), defined as complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) and immune-related RECIST (iRECIST) criteria.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SV-BR-1-GM Monotherapy</title>
            <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate</title>
          <description>Objective response rate (ORR), defined as complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) and immune-related RECIST (iRECIST) criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Non-progression of Tumors</title>
        <description>Non-progressive rate, defined as CR, PR or stable disease (SD) per RECIST and iRECIST criteria</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SV-BR-1-GM Monotherapy</title>
            <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Non-progression of Tumors</title>
          <description>Non-progressive rate, defined as CR, PR or stable disease (SD) per RECIST and iRECIST criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durability of Tumor Response</title>
        <description>Durability of response, as defined as complete response (disappearance of all tumors), partial response (30% or greater reduction in the sum of diameters of target lesions (tumors) with stable disease in non-target lesions) or stable disease (less than 20% increase in the sum of diameters of target lesions with no new lesions appearing) by evaluating those patients eligible to complete the optional treatments from 9-12 months</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SV-BR-1-GM Monotherapy</title>
            <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
          </group>
        </group_list>
        <measure>
          <title>Durability of Tumor Response</title>
          <description>Durability of response, as defined as complete response (disappearance of all tumors), partial response (30% or greater reduction in the sum of diameters of target lesions (tumors) with stable disease in non-target lesions) or stable disease (less than 20% increase in the sum of diameters of target lesions with no new lesions appearing) by evaluating those patients eligible to complete the optional treatments from 9-12 months</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.5" lower_limit="79" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immune Responses to Vaccine</title>
        <description>To assess immune responses to SV-BR-1-GM, and to recall antigens, if any, as measured by DTH skin tests and/or other immunological tests</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Using the SF-36 Health Survey</title>
        <description>To measure the quality of life (QOL) of participants using the SF-36 Health Survey, which includes measures of General Health, Limitations of Activity, Physical Health Problems, Emotional Health Problems, Social Activities, Energy and Emotions.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Weight</title>
        <description>To measure changes in weight.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Performance Status</title>
        <description>To measure changes in performance status using the Eastern Cooperative Oncology Group (ECOG) scale</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pain (Pain Scale)</title>
        <description>To measure changes in pain using a scale from None to Very Mild to Mild to Moderate to Severe to Very Severe</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year</time_frame>
      <desc>Used CTCAE V4.03 to determine adverse event intensity</desc>
      <group_list>
        <group group_id="E1">
          <title>SV-BR-1-GM Monotherapy</title>
          <description>Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation&#xD;
SV-BR-1-GM: See above&#xD;
Cyclophosphamide: Low dose pre-treatment to reduce regulatory T cells&#xD;
Interferon-alpha-2b: Low dose given in the vaccine site to boost the immune response</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Restrictive Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (19.0)">Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Worsening of Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (19.0)">Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (19.0)">Erythema, injection site</sub_title>
                <counts group_id="E1" events="42" subjects_affected="11" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritis, injection site</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Induration, injection site</sub_title>
                <counts group_id="E1" events="31" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>GGTP increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>ALT Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>AST Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hematocrit Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocytes Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One patient dropped out after receiving cyclophosphamide and did not receive SV-BR-1-GM.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William Williams</name_or_title>
      <organization>BriaCell Therapeutics Corporation</organization>
      <phone>1-888-485-6340</phone>
      <email>williams@briacell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

